- Home
- TMQ vs VOR Comparison
TMQ vs VOR Comparison
Compare TMQ & VOR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | TMQ | VOR |
|---|---|---|
| Founded | 2004 | 2015 |
| Country | Canada | United States |
| Employees | N/A | N/A |
| Industry | Precious Metals | Biotechnology: Pharmaceutical Preparations |
| Sector | Basic Materials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 705.7M | 702.4M |
| IPO Year | 2012 | 2021 |
Fundamental Metrics
Financial Performance| Metric | TMQ | VOR |
|---|---|---|
| Price | $4.34 | $14.63 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 10 |
| Target Price | N/A | ★ $45.33 |
| AVG Volume (30 Days) | ★ 2.3M | 1.1M |
| Earning Date | 04-02-2026 | 05-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.17 | $0.13 |
| 52 Week High | $11.29 | $49.95 |
Technical Indicators
Market Signals| Indicator | TMQ | VOR |
|---|---|---|
| Relative Strength Index (RSI) | 53.87 | 49.15 |
| Support Level | $4.26 | $11.74 |
| Resistance Level | $4.46 | $14.73 |
| Average True Range (ATR) | 0.24 | 1.00 |
| MACD | 0.00 | -0.16 |
| Stochastic Oscillator | 46.71 | 32.19 |
Price Performance
Historical ComparisonAbout TMQ Trilogy Metals Inc.
Trilogy Metals Inc is an exploration stage company engaged in mineral exploration. The company focuses on exploring and developing its mineral resource properties, which include the Upper Kobuk Mineral Projects (UKMP or UKMP Projects), in the Ambler mining district located in Alaska, the USA. Its properties include the Arctic copper-zinc-gold-silver project and other mineralized targets within a volcanogenic massive sulfide belt, and it also has a bornite carbonate-hosted copper project.
About VOR Vor Biopharma Inc.
Vor Biopharma Inc is a clinical-stage biopharmaceutical company focused on developing novel therapies for the treatment of autoimmune diseases. Its program, telitacicept, is a potential first- and best-in-class dual BAFF/APRIL inhibitor designed to suppress the signaling pathways that drive the maturation, proliferation, and survival of harmful B cells, including self-reactive B cells, thereby reducing autoantibody production and preventing downstream tissue damage.